Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial
Susan L. Samson(Jacksonville College), Mandeep Bajaj(All India Institute of Medical Sciences)
Cited by 107
Related Papers
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary
|Endocrine Practice|2020|603
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
|Endocrine Practice|2022|465
<i>SPTSSA</i> variants alter sphingolipid synthesis and cause a complex hereditary spastic paraplegia
|Brain|2023|34
A resource of lipidomics and metabolomics data from individuals with undiagnosed diseases
|Scientific Data|2021|18